NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

THE first Bahraini citizen to receive treatment outside the US for sickle cell disease using a bone marrow transplantation technology with Casgevy, expressed appreciation for his meeting with His ...

With that as the backdrop, if you have $3,000 otherwise-idle bucks you're ready to put to work in the market, here's a closer look at three of your best bets right now. Roku's role within the ...

ABU DHABI, 18th May, 2026 (WAM) -- The United Arab Emirates continues to strengthen its position as a global leader in adopting innovative medicines and advanced treatments that enhance patient care ...

BOSTON – Two investigational ex vivo gene-editing therapies may enable beta-thalassemia patients to forgo transfusions for years, according to data from early trials of the treatments presented at the ...

“MaxCyte reported $9.7 million of total revenue, including $6.2 million of core revenue and $3.4 million of SPL program-related revenue, which consists of milestones and royalties,” and CEO Maher ...

Hello, everyone. My name is Alec Stranahan. I cover CRISPR Therapeutics at Bank of America. Thanks for joining this session with CRISPR. And pleased to introduce Sam Kulkarni, the Chief Executive ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bullish sentiment for CRISPR Therapeutics makes sense given the potential catalysts ahead. The stock could soar if it delivers strong clinical progress over the next 12 months. Still, investors should ...

In 2026, the biotech landscape has undergone a seismic shift, moving beyond the hype cycles of the past decade into a phase of tangible, life-saving applications. With the first wave of CRISPR-based ...

The biotech landscape of 2026 is defined by a decisive shift: innovations once confined to early-stage research are now entering clinical validation and regulatory review. With the FDA’s new 'Roadmap ...